“This is for sure going to work,” Surge Biswas, PhD, CEO of Nabla Bio, told me when asked to weigh in on the future outlook of de novo antibody design, or designing antibodies not found in nature.

Nxera will hold an exclusive licence for the antibody assets globally, granting full rights for their development and commercialisation. The initial project will focus on antibodies’ design with ...

However, the new antibody design addresses these challenges. Its modular structure includes a bispecific antibody produced in ...

Cancer scientists say they have engineered a new type of super-strong antibody which could be used to boost the immune systems of patients fighting the disease. Experts from the University of ...

Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims ...

Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington ...

Monoclonal antibody design begins with identifying antibodies that bind to a specific target. One way to do this is to isolate antibody producing B-cells from human blood samples.

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

Nxera Pharma, previously known as Sosei Heptares or the Sosei Group, has entered a collaboration and licensing agreement with Antiverse to design antibodies for G-protein coupled receptors (GPCRs ...